Effect of HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients

Studies have shown that HMG-CoA reductase inhibitors (statins) play an important role in the prevention and treatment of atherosclerosis and hyperlipidemia. The aim of this study was to investigate the effect of 3-month treatment with simvastatin on serum levels of Insulin-Like Growth Factor-1 (IGF-...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological reports 2009-07, Vol.61 (4), p.654-664
Main Authors: Szkodziński, Janusz, Romanowski, Wojciech, Hudzik, Bartosz, Kaszuba, Andrzej, Nowakowska-Zajdel, Ewa, Szkilnik, Ryszard, Pietrasińska, Barbara, Zubelewicz-Szkodzińska, Barbara
Format: Article
Language:English
Subjects:
Adult
Biomarkers - blood
Dietary Fats - administration & dosage
Dietary Fats - adverse effects
Dietary Fats - blood
Drug Safety and Pharmacovigilance
HMG-CoA reductase inhibitors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
hypercholesterolemia
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
IGF-1
Insulin-Like Growth Factor I - antagonists & inhibitors
Insulin-Like Growth Factor I - metabolism
Male
Middle Aged
Pharmacotherapy
Pharmacy
Simvastatin - pharmacology
Simvastatin - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies have shown that HMG-CoA reductase inhibitors (statins) play an important role in the prevention and treatment of atherosclerosis and hyperlipidemia. The aim of this study was to investigate the effect of 3-month treatment with simvastatin on serum levels of Insulin-Like Growth Factor-1 (IGF-1) in patients with diagnosed hypercholesterolemia. In total, 156 patients with hypercholesterolemia were recruited for the study. The inclusion criteria for this study were designed to allow the enrollment of a representative group of patients for cytokine studies. The patients were divided into two groups: (1) patients with a mild-tomoderate risk of heart disease, who had total cholesterol (TC) < 300mg/dl (7.8mmol/l), LDL-cholesterol>210mg/dl (5.4mmol/l), and who lacked risk factors for coronary artery disease (CAD) after treatment with a diet for 3 months; (2) patients with a high-to very high risk of CAD, who had TC>300mg/dl (7.8mmol/l), LDL-cholesterol>210mg/dl (5.4mmol/l), and at least two risk factors for CAD after treatment with a diet and administration of simvastatin (20mg/day) for a three month period. The control group consisted often healthy volunteers who each had a normal lipid profile. Total cholesterol, LDL-cholesterol and IGF-1 concentrations were measured at baseline and either after six months of dietary supplementation (first group) or after three months of dietary supplementation and three months of simvastatin treatment (second group). Conclusions: In patients with mild-tomoderate risk of CAD, a decreased serum concentration of IGF-1 was observed three months after beginning a low-fat diet. However, no changes in the serum concentration of IGF-1 were noted in patients with high-to-very high risk of CAD. Additional three-month treatment with simvastatin decreased the serum concentration of IGF-1.
ISSN:1734-1140
2299-5684
DOI:10.1016/S1734-1140(09)70117-3